Abemaciclib and Letrozole in Metastatic Male Breast Cancer
ABSTRACT Background Male breast cancer is a very rare disease and only accounts for around 1% of all breast cancers. The treatment strategies are based on those used for breast cancer in women. So far, there is a lack of randomized data to support specific treatment modalities in men. To our knowled...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.70054 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850270295094460416 |
|---|---|
| author | Leon Schönfeld Christian Möhring Rouven Strobel Hanns Leonhard Kaatsch Stephan Waldeck Ulrike Wagner |
| author_facet | Leon Schönfeld Christian Möhring Rouven Strobel Hanns Leonhard Kaatsch Stephan Waldeck Ulrike Wagner |
| author_sort | Leon Schönfeld |
| collection | DOAJ |
| description | ABSTRACT Background Male breast cancer is a very rare disease and only accounts for around 1% of all breast cancers. The treatment strategies are based on those used for breast cancer in women. So far, there is a lack of randomized data to support specific treatment modalities in men. To our knowledge, a therapeutic approach with a combination of letrozole and abemaciclib has not yet been described for a male patient with metastatic breast cancer. Case Description Here, we report a case of a male patient with advanced metastatic breast cancer treated with a combination of letrozole and abemaciclib. The therapy was well tolerated with no reported side effects. The follow‐up CT showed regression of the primary tumor mass and the lymph nodes and soft tissue metastases. Conclusion In summary, this case report clearly shows the effectiveness of the therapeutic approach and should be discussed for the treatment of future patients. |
| format | Article |
| id | doaj-art-e021560db8cc40209609de1a565691d1 |
| institution | OA Journals |
| issn | 2573-8348 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj-art-e021560db8cc40209609de1a565691d12025-08-20T01:52:42ZengWileyCancer Reports2573-83482024-11-01711n/an/a10.1002/cnr2.70054Abemaciclib and Letrozole in Metastatic Male Breast CancerLeon Schönfeld0Christian Möhring1Rouven Strobel2Hanns Leonhard Kaatsch3Stephan Waldeck4Ulrike Wagner5Department for Internal Medicine Bundeswehr Central Hospital Koblenz GermanyDepartment for Internal Medicine Bundeswehr Central Hospital Koblenz GermanyDepartment for Internal Medicine Bundeswehr Central Hospital Koblenz GermanyDepartment for Diagnostic and Interventional Radiology and Neuroradiology Bundeswehr Central Hospital Koblenz GermanyDepartment for Diagnostic and Interventional Radiology and Neuroradiology Bundeswehr Central Hospital Koblenz GermanyDepartment for Internal Medicine Bundeswehr Central Hospital Koblenz GermanyABSTRACT Background Male breast cancer is a very rare disease and only accounts for around 1% of all breast cancers. The treatment strategies are based on those used for breast cancer in women. So far, there is a lack of randomized data to support specific treatment modalities in men. To our knowledge, a therapeutic approach with a combination of letrozole and abemaciclib has not yet been described for a male patient with metastatic breast cancer. Case Description Here, we report a case of a male patient with advanced metastatic breast cancer treated with a combination of letrozole and abemaciclib. The therapy was well tolerated with no reported side effects. The follow‐up CT showed regression of the primary tumor mass and the lymph nodes and soft tissue metastases. Conclusion In summary, this case report clearly shows the effectiveness of the therapeutic approach and should be discussed for the treatment of future patients.https://doi.org/10.1002/cnr2.70054abemaciclibCDK4/6 inhibitormale breast cancermetastatic disease |
| spellingShingle | Leon Schönfeld Christian Möhring Rouven Strobel Hanns Leonhard Kaatsch Stephan Waldeck Ulrike Wagner Abemaciclib and Letrozole in Metastatic Male Breast Cancer Cancer Reports abemaciclib CDK4/6 inhibitor male breast cancer metastatic disease |
| title | Abemaciclib and Letrozole in Metastatic Male Breast Cancer |
| title_full | Abemaciclib and Letrozole in Metastatic Male Breast Cancer |
| title_fullStr | Abemaciclib and Letrozole in Metastatic Male Breast Cancer |
| title_full_unstemmed | Abemaciclib and Letrozole in Metastatic Male Breast Cancer |
| title_short | Abemaciclib and Letrozole in Metastatic Male Breast Cancer |
| title_sort | abemaciclib and letrozole in metastatic male breast cancer |
| topic | abemaciclib CDK4/6 inhibitor male breast cancer metastatic disease |
| url | https://doi.org/10.1002/cnr2.70054 |
| work_keys_str_mv | AT leonschonfeld abemaciclibandletrozoleinmetastaticmalebreastcancer AT christianmohring abemaciclibandletrozoleinmetastaticmalebreastcancer AT rouvenstrobel abemaciclibandletrozoleinmetastaticmalebreastcancer AT hannsleonhardkaatsch abemaciclibandletrozoleinmetastaticmalebreastcancer AT stephanwaldeck abemaciclibandletrozoleinmetastaticmalebreastcancer AT ulrikewagner abemaciclibandletrozoleinmetastaticmalebreastcancer |